Biogen (NASDAQ:BIIB) Hits New 52-Week High – Time to Buy?

Shares of Biogen Inc. (NASDAQ:BIIB) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $222.86 and last traded at $222.8450, with a volume of 357141 shares traded. The stock had previously closed at $216.04.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: China approved LEQEMBI’s subcutaneous autoinjector formulation for initiation treatment in early Alzheimer’s disease. The once-weekly, at-home option expands access beyond hospital-based infusions, could improve adherence, and may reduce clinic and healthcare-resource requirements. Launch is planned during Eisai’s fiscal 2026. Biogen co-commercializes LEQEMBI with Eisai, although Eisai leads development and has final decision-making authority. China approval of LEQEMBI subcutaneous formulation
• Positive Sentiment: U.S. patients can now receive LEQEMBI IQLIK at home through a weekly prefilled syringe or autoinjector, giving Biogen and Eisai a more convenient alternative to infusion-based therapy. This could lower treatment barriers and support broader commercial uptake of the Alzheimer’s franchise. Biogen brings at-home weekly Alzheimer’s injection to U.S. patients
• Positive Sentiment: Four-year data for zorevunersen, developed with Stoke Therapeutics, showed durable seizure reductions and continuing improvements in cognition and behavior for Dravet syndrome patients receiving the treatment alongside standard care. The reported completion of Phase 3 EMPEROR enrollment provides an additional late-stage development milestone and supports Biogen’s efforts to build growth beyond its established products. Long-term zorevunersen clinical data
• Neutral Sentiment: Investors remain focused on Biogen’s diversification strategy. The RayThera acquisition adds an early-stage immunology program, but its lead drug is only in Phase 1, making the deal a long-term opportunity rather than an immediate earnings contributor. Biogen’s immunology acquisition and balance sheet
• Negative Sentiment: Valuation and execution risks could limit further upside. BIIB is trading near its 52-week high, while earnings-based measures characterize the shares as expensive; zorevunersen remains investigational, and LEQEMBI’s subcutaneous formulation can cause injection-related reactions and still requires MRI monitoring for ARIA. Biogen valuation and Dravet data analysis

Wall Street Analyst Weigh In

A number of research analysts have recently commented on BIIB shares. Guggenheim raised their price target on Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. UBS Group upped their price objective on shares of Biogen from $225.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. HSBC reiterated a “reduce” rating and issued a $157.00 target price on shares of Biogen in a research report on Monday, July 6th. Weiss Ratings downgraded shares of Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, August 12th. Finally, Citigroup upped their price target on shares of Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $228.50.

Biogen Stock Performance

The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The firm has a market cap of $33.17 billion, a price-to-earnings ratio of 39.74, a price-to-earnings-growth ratio of 2.46 and a beta of 0.17. The company has a fifty day moving average price of $209.44 and a two-hundred day moving average price of $196.45.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period in the previous year, the company earned $5.47 earnings per share. Biogen’s revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts expect that Biogen Inc. will post 12.39 EPS for the current year.

Institutional Trading of Biogen

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bell Investment Advisors Inc bought a new stake in Biogen during the second quarter worth approximately $27,000. Reflection Asset Management bought a new position in shares of Biogen in the fourth quarter valued at $25,000. Root Financial Partners LLC increased its holdings in shares of Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. MV Capital Management Inc. acquired a new stake in shares of Biogen during the 4th quarter valued at $34,000. Finally, Strive Financial Group LLC acquired a new stake in shares of Biogen during the 4th quarter valued at $35,000. 87.93% of the stock is currently owned by institutional investors.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.